Skip to content

Gingival Crevicular Fluid Alkaline Phosphatase as Skeletal Growth Indicator

Gingival Crevicular Fluid Alkaline Phosphatase Activity as a Biomarker of Skeletal Maturation in Comparison to Modified Middle Phalanx of The Middle Finger (MP3) Method in a Sample of Growing Egyptian Females

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04452071
Enrollment
92
Registered
2020-06-30
Start date
2019-11-26
Completion date
2020-01-10
Last updated
2020-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Indictaor

Brief summary

Determination of the pubertal growth spurt in Egyptian female patients using gingival crevicular fluid alkaline phosphatase

Detailed description

assessment of the pubertal growth spurt in growing Egyptian female patients by using a simple, quick and easy method, through taking a gingival crevicular fluid alkaline phosphatase sample and measuring its concentration. Comparing the concentration of GCF ALP to the standardized middle phalanax of the middle finger MP3 we can predict if it can be an accurate and reliable method as skeletal growth indicator.

Interventions

periapical xray on the middle phalanax of the middle finger

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
7 Years to 16 Years

Inclusion criteria

1. Gender: only female subjects will be included. 2. Age between 7-16 years old 3. Intermediate or late mixed dentition and permanent dentition 4. Good general health with absence of any nutritional problems or bony disease 5. No usage of any anti-inflammatories or antibiotics in the month preceding the study 6. Fully erupted upper and lower central incisors for sample collection 7. Good gingival and periodontal health as indicated by Probing depth (PD) values that should not exceed 3 mm for the whole dentition. 8. Willingness to participate in the study and sign the informed consent form

Exclusion criteria

1. Male adolescent subjects 2. Periodontal and /or gingival disease 3. Systemic and/or bone disease 3\. Growth abnormality

Design outcomes

Primary

MeasureTime frameDescription
GCF ALP concentrationimmediately after sample collectionconcentration of gingival crevicular fluid alkaline phosphatase
MP3immediately after taking x-raysperiapical x-ray of the middle phalanax of the middle finger

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026